In the control group, T2DM participants received either placebo or other hypoglycemic agents, including metformin, insulin, and alpha‐glucosidase inhibitors, while participants with obesity received only placebo. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.